董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edward Mathers | 男 | Director | 65 | 8.11万美元 | 未持股 | 2025-08-22 |
| Jennifer Good | 女 | President and Chief Executive Officer and Director and interim Principal Financial Officer | 60 | 89.81万美元 | 未持股 | 2025-08-22 |
| Dominick Colangelo | 男 | Director | 61 | 8.86万美元 | 未持股 | 2025-08-22 |
| Michael Heffernan | 男 | Director | 61 | 9.36万美元 | 未持股 | 2025-08-22 |
| Anne VanLent | 女 | Director | 77 | 9.51万美元 | 未持股 | 2025-08-22 |
| David Meeker | 男 | Chairman and Director | 70 | 10.61万美元 | 未持股 | 2025-08-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jennifer Good | 女 | President and Chief Executive Officer and Director and interim Principal Financial Officer | 60 | 89.81万美元 | 未持股 | 2025-08-22 |
| Thomas Sciascia | 男 | co-founder and Chief Scientific Officer | 71 | 57.73万美元 | 未持股 | 2025-08-22 |
| James Cassella | 男 | Chief Development Officer | 70 | 8.21万美元 | 未持股 | 2025-08-22 |
| Farrell Simon | 男 | Chief Commercial Officer | 43 | 未披露 | 未持股 | 2025-08-22 |
董事简历
中英对照 | 中文 | 英文- Edward Mathers
-
Edward Mathers，自Senti Biosciences，Inc.业务合并于2022年6月结束以来一直担任Senti Biosciences，Inc.董事会成员，在Senti Biosciences，Inc.业务合并之前，自2016年7月起担任Legacy Senti董事会成员。Mathers先生自2019年11月起担任New Enterprise Associates，Inc.（NEA）的普通合伙人，该公司是一家专注于技术和医疗保健投资的私营风险投资公司，在此之前，于2008年8月至2019年10月担任NEA的合伙人。在加入NEA之前，Mathers先生曾在生物制药公司MedImmune，Inc.担任企业发展和风险投资执行副总裁，并于2008年6月至2022年6月期间领导其风险投资子公司MedImmune Ventures，Inc.。Mathers先生目前担任Affinia Therapeutics，Code Biotherapeutics，Inc.，Inozyme Pharma, Inc.（NASDAQ：INZY），Inversago Pharma，MBX Biosciences，Inc.，ObsEva SA（NASDAQ：OBSV），Reneo Pharmaceuticals, Inc.（NASDAQ：RPHM），TERM4（NASDAQ：TERM5），Rhythm Pharmaceuticals, Inc.TERM6（NASDAQ：RYTM），Shape Therapeutics Inc.，Sorriso Pharmaceuticals，Inc.，SpliceBio，SL，Synlogic, Inc.TERM8（NASDAQ：SYBX）原名自2017年10月至2022年12月被上市生物制药公司礼来 and Company（NYSE：LLY）、Mirum Pharmaceuticals, Inc.，Inc.（NASDAQ：MIRM）收购，自2018年11月至2022年9月，上市生物制药公司Lumos Pharma, Inc.，TERM4，Inc.（NASDAQ：LUMO）于2014年1月至2020年3月与NewLink Genetics Corporation（NASDAQ：NLINK）、Liquidia Technologies, Inc.TERM6（NASDAQ：LQDA）合并，上市生物制药公司TERM6，Inc.（NASDAQ：TERM7）于2009年4月至2019年5月被上市生物制药公司收购，而Ra Pharmaceuticals, Inc.，Inc.（NASDAQ：RARX）于2010年2月至2020年4月被UCIC收购马瑟斯先生在北卡罗来纳州立大学获得化学学士学位。
Edward Mathers has served as a member of Synlogic, Inc. Board since October 2012. Mr. Mathers previoly served on the Private Synlogic board of directors since July 2014. Mr. Mathers is a General Partner at NEA, a private venture capital firm focing on technology and healthcare investments. Mr. Mathers serves on the board of directors of the following publicly traded pharmaceutical companies: Trevi Therapeutics, Inc., Rhythm Pharmaceuticals, Inc., OnKure Therapeutics, Inc., formerly known as Reneo Pharmaceuticals, Inc., MBX Biosciences, Inc. and Senti Biosciences, Inc. Mr. Mathers also serves on the board of directors of several privately held companies. Mr. Mathers previoly served on the board of directors of the following publicly traded companies: ObsEva SA, Mirum Pharmaceuticals, Inc., Akouos, Inc., Lumos Pharma, Inc., and Ra Pharmaceuticals, Inc. From 2002 to 2008, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune, Inc., a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, Mr. Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, a biotechnology company. Previoly, Mr. Mathers spent 15 years at Glaxo llcome, Inc. (GlaxoSmithKline), a pharmaceutical company, where he held vario sales and marketing positions. Mr. Mathers received a B.S. in Chemistry from North Carolina State University. - Edward Mathers，自Senti Biosciences，Inc.业务合并于2022年6月结束以来一直担任Senti Biosciences，Inc.董事会成员，在Senti Biosciences，Inc.业务合并之前，自2016年7月起担任Legacy Senti董事会成员。Mathers先生自2019年11月起担任New Enterprise Associates，Inc.（NEA）的普通合伙人，该公司是一家专注于技术和医疗保健投资的私营风险投资公司，在此之前，于2008年8月至2019年10月担任NEA的合伙人。在加入NEA之前，Mathers先生曾在生物制药公司MedImmune，Inc.担任企业发展和风险投资执行副总裁，并于2008年6月至2022年6月期间领导其风险投资子公司MedImmune Ventures，Inc.。Mathers先生目前担任Affinia Therapeutics，Code Biotherapeutics，Inc.，Inozyme Pharma, Inc.（NASDAQ：INZY），Inversago Pharma，MBX Biosciences，Inc.，ObsEva SA（NASDAQ：OBSV），Reneo Pharmaceuticals, Inc.（NASDAQ：RPHM），TERM4（NASDAQ：TERM5），Rhythm Pharmaceuticals, Inc.TERM6（NASDAQ：RYTM），Shape Therapeutics Inc.，Sorriso Pharmaceuticals，Inc.，SpliceBio，SL，Synlogic, Inc.TERM8（NASDAQ：SYBX）原名自2017年10月至2022年12月被上市生物制药公司礼来 and Company（NYSE：LLY）、Mirum Pharmaceuticals, Inc.，Inc.（NASDAQ：MIRM）收购，自2018年11月至2022年9月，上市生物制药公司Lumos Pharma, Inc.，TERM4，Inc.（NASDAQ：LUMO）于2014年1月至2020年3月与NewLink Genetics Corporation（NASDAQ：NLINK）、Liquidia Technologies, Inc.TERM6（NASDAQ：LQDA）合并，上市生物制药公司TERM6，Inc.（NASDAQ：TERM7）于2009年4月至2019年5月被上市生物制药公司收购，而Ra Pharmaceuticals, Inc.，Inc.（NASDAQ：RARX）于2010年2月至2020年4月被UCIC收购马瑟斯先生在北卡罗来纳州立大学获得化学学士学位。
- Edward Mathers has served as a member of Synlogic, Inc. Board since October 2012. Mr. Mathers previoly served on the Private Synlogic board of directors since July 2014. Mr. Mathers is a General Partner at NEA, a private venture capital firm focing on technology and healthcare investments. Mr. Mathers serves on the board of directors of the following publicly traded pharmaceutical companies: Trevi Therapeutics, Inc., Rhythm Pharmaceuticals, Inc., OnKure Therapeutics, Inc., formerly known as Reneo Pharmaceuticals, Inc., MBX Biosciences, Inc. and Senti Biosciences, Inc. Mr. Mathers also serves on the board of directors of several privately held companies. Mr. Mathers previoly served on the board of directors of the following publicly traded companies: ObsEva SA, Mirum Pharmaceuticals, Inc., Akouos, Inc., Lumos Pharma, Inc., and Ra Pharmaceuticals, Inc. From 2002 to 2008, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune, Inc., a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, Mr. Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, a biotechnology company. Previoly, Mr. Mathers spent 15 years at Glaxo llcome, Inc. (GlaxoSmithKline), a pharmaceutical company, where he held vario sales and marketing positions. Mr. Mathers received a B.S. in Chemistry from North Carolina State University.
- Jennifer Good
-
Jennifer Good是我们的联合创始人，自2011年3月成立以来一直担任我们的董事会成员以及我们的总裁兼首席执行官。此前，Good女士曾于1997年至2010年在Penwest Pharmaceuticals Co.（Penwest）任职，担任过多个职位，包括总裁兼首席执行官、首席运营官和首席财务官。Good女士自2017年9月起担任瞻博制药公司（一家公开上市的梦百合公司）的董事会成员，直到2018年8月该公司被Catalent，Inc.收购。Good女士自2011年以来还担任Friedreich&；8217；S共济失调Research Alliance FARA的董事会成员，这是一家为治疗Friedreich&；8217；S共济失调推进治疗的患者倡导团体。Good女士于1987年在太平洋路德大学（Pacific Lutheran University）获得会计学方向的工商管理学士学位，是华盛顿州许可的注册会计师，尽管她的许可目前不活跃。
Jennifer Good,served at Penwest Pharmaceuticals Co., or Penwest, from 1997 to 2010, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Ms. Good has served on the board of Rhythm Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since June 2019. Ms. Good has also served as a board member of the Friedreich's Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich's Ataxia, since 2011. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. - Jennifer Good是我们的联合创始人，自2011年3月成立以来一直担任我们的董事会成员以及我们的总裁兼首席执行官。此前，Good女士曾于1997年至2010年在Penwest Pharmaceuticals Co.（Penwest）任职，担任过多个职位，包括总裁兼首席执行官、首席运营官和首席财务官。Good女士自2017年9月起担任瞻博制药公司（一家公开上市的梦百合公司）的董事会成员，直到2018年8月该公司被Catalent，Inc.收购。Good女士自2011年以来还担任Friedreich&；8217；S共济失调Research Alliance FARA的董事会成员，这是一家为治疗Friedreich&；8217；S共济失调推进治疗的患者倡导团体。Good女士于1987年在太平洋路德大学（Pacific Lutheran University）获得会计学方向的工商管理学士学位，是华盛顿州许可的注册会计师，尽管她的许可目前不活跃。
- Jennifer Good,served at Penwest Pharmaceuticals Co., or Penwest, from 1997 to 2010, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Ms. Good has served on the board of Rhythm Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since June 2019. Ms. Good has also served as a board member of the Friedreich's Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich's Ataxia, since 2011. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive.
- Dominick Colangelo
-
Dominick Colangelo，自2020年6月起在Trevi Therapeutics, Inc.董事会任职。Colangelo先生自2013年3月起担任上市的商业阶段生物制药公司Vericel Corporation的总裁兼首席执行官和董事。Colangelo先生在生物制药行业拥有20多年的执行管理和企业发展经验，其中包括在上市制药公司礼来公司任职近十年。在他的职业生涯中，他在产品开发、药品运营、销售和市场营销以及企业发展方面担任过各种责任越来越大的高管职位。他在跨多个治疗领域的产品的收购、开发和商业化方面拥有丰富的经验。在礼来任职期间，他曾担任礼来糖尿病产品组战略和业务发展总监等职务，还曾担任Lilly Ventures的创始董事总经理。Colangelo先生获得了布法罗纽约州立大学会计学学士学位和杜克大学法学院法学博士学位。
Dominick Colangelo,has served as President and Chief Executive Officer and a director of Vericel Corporation, a publicly traded commercial-stage biopharmaceutical company, since March 2013. Mr. Colangelo has more than 20 years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company, a publicly traded pharmaceutical company. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing and corporate development. He has extensive experience in the acquisition, development and commercialization of products across a variety of therapeutic areas. Mr. Colangelo received a B.S.B.A. in Accounting from the State University of New York at Buffalo and a J.D. from the Duke University School of Law. - Dominick Colangelo，自2020年6月起在Trevi Therapeutics, Inc.董事会任职。Colangelo先生自2013年3月起担任上市的商业阶段生物制药公司Vericel Corporation的总裁兼首席执行官和董事。Colangelo先生在生物制药行业拥有20多年的执行管理和企业发展经验，其中包括在上市制药公司礼来公司任职近十年。在他的职业生涯中，他在产品开发、药品运营、销售和市场营销以及企业发展方面担任过各种责任越来越大的高管职位。他在跨多个治疗领域的产品的收购、开发和商业化方面拥有丰富的经验。在礼来任职期间，他曾担任礼来糖尿病产品组战略和业务发展总监等职务，还曾担任Lilly Ventures的创始董事总经理。Colangelo先生获得了布法罗纽约州立大学会计学学士学位和杜克大学法学院法学博士学位。
- Dominick Colangelo,has served as President and Chief Executive Officer and a director of Vericel Corporation, a publicly traded commercial-stage biopharmaceutical company, since March 2013. Mr. Colangelo has more than 20 years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company, a publicly traded pharmaceutical company. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing and corporate development. He has extensive experience in the acquisition, development and commercialization of products across a variety of therapeutic areas. Mr. Colangelo received a B.S.B.A. in Accounting from the State University of New York at Buffalo and a J.D. from the Duke University School of Law.
- Michael Heffernan
-
Michael Heffernan自2017年2月以来一直担任我们的董事会成员。Heffernan先生于2002年10月至2018年7月担任Collegium制药公司（一家公开上市的制药公司）的总裁，首席执行官兼董事，随后他过渡到董事会主席。他还创立了Precision Dermatology，前身是Onset Therapeutics，LLC，这是一家专注于皮肤病学的公司，并从2005年到2010年担任其总裁兼首席执行官。Heffernan先生此前于1994年至1999年创立并担任Clinical Studies Ltd.的总裁兼首席执行官，该公司是一家制药合同研究组织，被出售给Phymatrix Corp.，随后于1999年至2002年担任Phymatrix的总裁兼首席执行官。Heffernan先生在礼来公司开始了他的职业生涯，在那里他担任过许多销售与市场营销的职务。Heffernan先生自2015年4月起担任Veloxis Pharmaceuticals A/S（一家专业制药公司，在纳斯达克OMX哥本哈根公开交易）的董事会成员，并自2016年4月起担任董事长。Heffernan先生自2016年4月起还担任KeryxBiopharmaceuticals，Inc.（一家上市制药公司）的董事会成员。赫弗南此前曾于2012年4月至2016年2月担任生物技术上市公司OcataTherapeutics公司（Chiesi USA，Inc.）的董事会成员，该公司现已更名为Chiesi USA，Inc.，是一家上市的专业制药公司，从2009年到2014年2月，他曾任职于几家私人控股公司的董事会。Heffernan先生于1987年毕业于康涅狄格大学（University of Connecticut），获得药学学士学位，是一名注册药剂师。
Michael Heffernan,is the Founder of Collegium Pharmaceutical, a publicly traded pharmaceutical company, or Collegium, and has served as the Chairman of its Board of Directors since July 2018. Mr. Heffernan served as Interim President and Chief Executive Officer of Collegium from May 2024 until November 2024 and as the President, Chief Executive Officer and a director of Collegium from October 2002 until July 2018. Most recently, Mr. Heffernan co-founded Avenge Bio, an oncology-focused biotechnology company, where he has served as Chairman since 2019 and served as Chief Executive Officer from January 2022 until May 2024. He has also been an advisor, investor and board member of a number of biopharmaceutical, medical device and healthcare services companies. Mr. Heffernan has served on the board of directors of Avalo Therapeutics, Inc., a publicly traded clinical stage biotechnology company, since March 2025 and was named the Chairman of the Board in March 2025. Mr. Heffernan has also served on the board of directors of Biohaven LTD, a publicly traded biopharmaceutical company, since January 2020. Mr. Heffernan previously served on the board of directors of Synlogic, Inc., a publicly traded clinical-stage biotechnology company, from December 2020 to February 2025, and Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company, from December 2018 until May 2022. Mr. Heffernan is a current member of the boards of several privately held companies. Mr. Heffernan earned his B.S. in Pharmacy from the University of Connecticut. - Michael Heffernan自2017年2月以来一直担任我们的董事会成员。Heffernan先生于2002年10月至2018年7月担任Collegium制药公司（一家公开上市的制药公司）的总裁，首席执行官兼董事，随后他过渡到董事会主席。他还创立了Precision Dermatology，前身是Onset Therapeutics，LLC，这是一家专注于皮肤病学的公司，并从2005年到2010年担任其总裁兼首席执行官。Heffernan先生此前于1994年至1999年创立并担任Clinical Studies Ltd.的总裁兼首席执行官，该公司是一家制药合同研究组织，被出售给Phymatrix Corp.，随后于1999年至2002年担任Phymatrix的总裁兼首席执行官。Heffernan先生在礼来公司开始了他的职业生涯，在那里他担任过许多销售与市场营销的职务。Heffernan先生自2015年4月起担任Veloxis Pharmaceuticals A/S（一家专业制药公司，在纳斯达克OMX哥本哈根公开交易）的董事会成员，并自2016年4月起担任董事长。Heffernan先生自2016年4月起还担任KeryxBiopharmaceuticals，Inc.（一家上市制药公司）的董事会成员。赫弗南此前曾于2012年4月至2016年2月担任生物技术上市公司OcataTherapeutics公司（Chiesi USA，Inc.）的董事会成员，该公司现已更名为Chiesi USA，Inc.，是一家上市的专业制药公司，从2009年到2014年2月，他曾任职于几家私人控股公司的董事会。Heffernan先生于1987年毕业于康涅狄格大学（University of Connecticut），获得药学学士学位，是一名注册药剂师。
- Michael Heffernan,is the Founder of Collegium Pharmaceutical, a publicly traded pharmaceutical company, or Collegium, and has served as the Chairman of its Board of Directors since July 2018. Mr. Heffernan served as Interim President and Chief Executive Officer of Collegium from May 2024 until November 2024 and as the President, Chief Executive Officer and a director of Collegium from October 2002 until July 2018. Most recently, Mr. Heffernan co-founded Avenge Bio, an oncology-focused biotechnology company, where he has served as Chairman since 2019 and served as Chief Executive Officer from January 2022 until May 2024. He has also been an advisor, investor and board member of a number of biopharmaceutical, medical device and healthcare services companies. Mr. Heffernan has served on the board of directors of Avalo Therapeutics, Inc., a publicly traded clinical stage biotechnology company, since March 2025 and was named the Chairman of the Board in March 2025. Mr. Heffernan has also served on the board of directors of Biohaven LTD, a publicly traded biopharmaceutical company, since January 2020. Mr. Heffernan previously served on the board of directors of Synlogic, Inc., a publicly traded clinical-stage biotechnology company, from December 2020 to February 2025, and Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company, from December 2018 until May 2022. Mr. Heffernan is a current member of the boards of several privately held companies. Mr. Heffernan earned his B.S. in Pharmacy from the University of Connecticut.
- Anne VanLent
-
Anne VanLent，自2013年4月起担任本公司董事。她现任AMV Advisors的总裁，为新兴的成长中的生命科学公司提供企业战略和财务咨询服务。从2002年5月至2008年4月，她担任 Barrier Therapeutics公司的执行副总裁和首席财务官，这是一个开发和销售的皮肤病处方产品的上市制药公司。从1997年7月至2001年10月，她担任Sarnoff Corporation的组合管理部执行副总裁，该司是一个多学科的研究和开发公司。1985-1993年，她担任生物制药上市公司 Liposome Company的高级副总裁兼首席财务官。她目前担任：Biota Pharmaceuticals的董事，审核委员会主席，提名和治理委员会委员；Ocera Therapeutics（原Tranzyme Pharma）的董事，审核委员会主席，提名和治理委员会主席； Onconova Therapeutics的董事，审核委员会主席，薪酬委员会成员，以上公司均是纳斯达克上市医药公司。在过去的五年中，2006-2012年间，她曾担任经营医疗设备的纳斯达克上市公司Integra Life Sciences Holdings的董事，并在该司担任审计委员会主席；纳斯达克上市制药公司Penwest Pharmaceuticals的董事，任期从1997年起直到2010年该司被出售给远藤制药，她于2002-2010年间担任Penwest审核委员会主席。她获得曼荷莲学院物理学学士学位。
Anne VanLent,has been President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly traded pharmaceutical company, from 2002 through 2008. Ms. VanLent served as a member of the board of directors and audit committee chair of ObsEva SA, a publicly traded biopharmaceutical company, from May 2021 until June 2023. Ms. VanLent also served as a member of the board of directors and audit committee chair of Applied Genetics Technologies Corporation, a publicly traded biotechnology company, from August 2016 until it was acquired by Syncona Limited in December 2022. From May 2013 to June 2020, Ms. VanLent served as a member of the board of directors of Vaxart, Inc. (formerly Aviragen Therapeutics, Inc.), a publicly traded biotechnology company. Ms. VanLent received a B.A. in physics from Mount Holyoke College. - Anne VanLent，自2013年4月起担任本公司董事。她现任AMV Advisors的总裁，为新兴的成长中的生命科学公司提供企业战略和财务咨询服务。从2002年5月至2008年4月，她担任 Barrier Therapeutics公司的执行副总裁和首席财务官，这是一个开发和销售的皮肤病处方产品的上市制药公司。从1997年7月至2001年10月，她担任Sarnoff Corporation的组合管理部执行副总裁，该司是一个多学科的研究和开发公司。1985-1993年，她担任生物制药上市公司 Liposome Company的高级副总裁兼首席财务官。她目前担任：Biota Pharmaceuticals的董事，审核委员会主席，提名和治理委员会委员；Ocera Therapeutics（原Tranzyme Pharma）的董事，审核委员会主席，提名和治理委员会主席； Onconova Therapeutics的董事，审核委员会主席，薪酬委员会成员，以上公司均是纳斯达克上市医药公司。在过去的五年中，2006-2012年间，她曾担任经营医疗设备的纳斯达克上市公司Integra Life Sciences Holdings的董事，并在该司担任审计委员会主席；纳斯达克上市制药公司Penwest Pharmaceuticals的董事，任期从1997年起直到2010年该司被出售给远藤制药，她于2002-2010年间担任Penwest审核委员会主席。她获得曼荷莲学院物理学学士学位。
- Anne VanLent,has been President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly traded pharmaceutical company, from 2002 through 2008. Ms. VanLent served as a member of the board of directors and audit committee chair of ObsEva SA, a publicly traded biopharmaceutical company, from May 2021 until June 2023. Ms. VanLent also served as a member of the board of directors and audit committee chair of Applied Genetics Technologies Corporation, a publicly traded biotechnology company, from August 2016 until it was acquired by Syncona Limited in December 2022. From May 2013 to June 2020, Ms. VanLent served as a member of the board of directors of Vaxart, Inc. (formerly Aviragen Therapeutics, Inc.), a publicly traded biotechnology company. Ms. VanLent received a B.A. in physics from Mount Holyoke College.
- David Meeker
-
David Meeker，自2020年7月起担任上市生物制药公司Rhythm Pharmaceuticals, Inc.总裁兼首席执行官，自2015年11月起担任董事，自2017年4月起担任董事长。在加入Rhythm制药之前，Meeker博士于2017年9月至2020年7月担任生物技术公司KSQTherapeutics，Inc.的首席执行官兼董事，并于2011年10月至2017年6月在生物制药公司赛诺菲 Genzyme工作，担任过多种职务，包括2011年10月至2016年1月担任赛诺菲（一家赛诺菲）公司Genzyme的总裁兼首席执行官，2012年至2017年6月担任TERM3执行委员会成员，并担任执行副总裁兼赛诺菲 Genzyme的负责人，该公司是赛诺菲负责罕见疾病、多发性硬化症的专科护理单位，肿瘤学和免疫学特许经营，2016年1月至2017年6月。在2011年赛诺菲收购Genzyme之前，Meeker博士于1994年开始在健赞工作，担任医疗总监，并担任越来越重要的职务，最终担任首席运营官。在加入Genzyme之前，Meeker博士是克利夫兰诊所肺部重症监护研究金的主任，也是俄亥俄州立大学的医学助理教授。Meeker博士自2021年1月起担任上市生物制药公司Pharvaris B.V.的董事长。Meeker博士还曾于2017年6月至2020年12月担任上市生物制药公司MyoKardia，Inc.的董事。Meeker博士拥有佛蒙特大学医学院的医学学位，并于2000年在哈佛商学院完成了高级管理课程。他在哈佛大学贝斯以色列医院完成了内科培训，在波士顿大学完成了肺/重症监护培训。
David Meeker,has served as President and Chief Executive Officer of Rhythm Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since July 2020, as a director since November 2015 and as chairman of the board since April 2017. Prior to joining Rhythm Pharmaceuticals, Dr. Meeker was Chief Executive Officer and director of KSQ Therapeutics, Inc., a biotechnology company, from September 2017 to July 2020 and worked at Sanofi Genzyme, a biopharmaceutical company, from October 2011 to June 2017, in a variety of roles, including President and Chief Executive Officer of Genzyme, a Sanofi Company, from October 2011 until January 2016, as a member of Sanofi's Executive Committee from 2012 to June 2017 and as Executive Vice President and head of Sanofi Genzyme, Sanofi's specialty care unit with responsibility for rare diseases, multiple sclerosis, oncology and immunology franchises, from January 2016 to June 2017. Prior to the acquisition of Genzyme by Sanofi in 2011, Dr. Meeker worked at Genzyme Corporation beginning in 1994 as medical director, and held positions of increasing responsibility, ultimately serving as Chief Operating Officer. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of Medicine at Ohio State University. Dr. Meeker has served as Chairman of Pharvaris B.V., a publicly traded biopharmaceutical company, since January 2021. Dr. Meeker also served as a director of MyoKardia, Inc., a publicly traded biopharmaceutical company, from June 2017 to December 2020. Dr. Meeker holds a medical degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School in 2000. He completed his internal medicine training at Harvard University's Beth Israel Hospital and pulmonary/critical care training at Boston University. - David Meeker，自2020年7月起担任上市生物制药公司Rhythm Pharmaceuticals, Inc.总裁兼首席执行官，自2015年11月起担任董事，自2017年4月起担任董事长。在加入Rhythm制药之前，Meeker博士于2017年9月至2020年7月担任生物技术公司KSQTherapeutics，Inc.的首席执行官兼董事，并于2011年10月至2017年6月在生物制药公司赛诺菲 Genzyme工作，担任过多种职务，包括2011年10月至2016年1月担任赛诺菲（一家赛诺菲）公司Genzyme的总裁兼首席执行官，2012年至2017年6月担任TERM3执行委员会成员，并担任执行副总裁兼赛诺菲 Genzyme的负责人，该公司是赛诺菲负责罕见疾病、多发性硬化症的专科护理单位，肿瘤学和免疫学特许经营，2016年1月至2017年6月。在2011年赛诺菲收购Genzyme之前，Meeker博士于1994年开始在健赞工作，担任医疗总监，并担任越来越重要的职务，最终担任首席运营官。在加入Genzyme之前，Meeker博士是克利夫兰诊所肺部重症监护研究金的主任，也是俄亥俄州立大学的医学助理教授。Meeker博士自2021年1月起担任上市生物制药公司Pharvaris B.V.的董事长。Meeker博士还曾于2017年6月至2020年12月担任上市生物制药公司MyoKardia，Inc.的董事。Meeker博士拥有佛蒙特大学医学院的医学学位，并于2000年在哈佛商学院完成了高级管理课程。他在哈佛大学贝斯以色列医院完成了内科培训，在波士顿大学完成了肺/重症监护培训。
- David Meeker,has served as President and Chief Executive Officer of Rhythm Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since July 2020, as a director since November 2015 and as chairman of the board since April 2017. Prior to joining Rhythm Pharmaceuticals, Dr. Meeker was Chief Executive Officer and director of KSQ Therapeutics, Inc., a biotechnology company, from September 2017 to July 2020 and worked at Sanofi Genzyme, a biopharmaceutical company, from October 2011 to June 2017, in a variety of roles, including President and Chief Executive Officer of Genzyme, a Sanofi Company, from October 2011 until January 2016, as a member of Sanofi's Executive Committee from 2012 to June 2017 and as Executive Vice President and head of Sanofi Genzyme, Sanofi's specialty care unit with responsibility for rare diseases, multiple sclerosis, oncology and immunology franchises, from January 2016 to June 2017. Prior to the acquisition of Genzyme by Sanofi in 2011, Dr. Meeker worked at Genzyme Corporation beginning in 1994 as medical director, and held positions of increasing responsibility, ultimately serving as Chief Operating Officer. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of Medicine at Ohio State University. Dr. Meeker has served as Chairman of Pharvaris B.V., a publicly traded biopharmaceutical company, since January 2021. Dr. Meeker also served as a director of MyoKardia, Inc., a publicly traded biopharmaceutical company, from June 2017 to December 2020. Dr. Meeker holds a medical degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School in 2000. He completed his internal medicine training at Harvard University's Beth Israel Hospital and pulmonary/critical care training at Boston University.
高管简历
中英对照 | 中文 | 英文- Jennifer Good
Jennifer Good是我们的联合创始人，自2011年3月成立以来一直担任我们的董事会成员以及我们的总裁兼首席执行官。此前，Good女士曾于1997年至2010年在Penwest Pharmaceuticals Co.（Penwest）任职，担任过多个职位，包括总裁兼首席执行官、首席运营官和首席财务官。Good女士自2017年9月起担任瞻博制药公司（一家公开上市的梦百合公司）的董事会成员，直到2018年8月该公司被Catalent，Inc.收购。Good女士自2011年以来还担任Friedreich&；8217；S共济失调Research Alliance FARA的董事会成员，这是一家为治疗Friedreich&；8217；S共济失调推进治疗的患者倡导团体。Good女士于1987年在太平洋路德大学（Pacific Lutheran University）获得会计学方向的工商管理学士学位，是华盛顿州许可的注册会计师，尽管她的许可目前不活跃。
Jennifer Good,served at Penwest Pharmaceuticals Co., or Penwest, from 1997 to 2010, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Ms. Good has served on the board of Rhythm Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since June 2019. Ms. Good has also served as a board member of the Friedreich's Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich's Ataxia, since 2011. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive.- Jennifer Good是我们的联合创始人，自2011年3月成立以来一直担任我们的董事会成员以及我们的总裁兼首席执行官。此前，Good女士曾于1997年至2010年在Penwest Pharmaceuticals Co.（Penwest）任职，担任过多个职位，包括总裁兼首席执行官、首席运营官和首席财务官。Good女士自2017年9月起担任瞻博制药公司（一家公开上市的梦百合公司）的董事会成员，直到2018年8月该公司被Catalent，Inc.收购。Good女士自2011年以来还担任Friedreich&；8217；S共济失调Research Alliance FARA的董事会成员，这是一家为治疗Friedreich&；8217；S共济失调推进治疗的患者倡导团体。Good女士于1987年在太平洋路德大学（Pacific Lutheran University）获得会计学方向的工商管理学士学位，是华盛顿州许可的注册会计师，尽管她的许可目前不活跃。
- Jennifer Good,served at Penwest Pharmaceuticals Co., or Penwest, from 1997 to 2010, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Ms. Good has served on the board of Rhythm Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since June 2019. Ms. Good has also served as a board member of the Friedreich's Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich's Ataxia, since 2011. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive.
- Thomas Sciascia
Thomas Sciascia是我们的联合创始人，自2011年3月我们成立以来一直担任我们的首席医疗官。此前，Sciascia从2001年到2010年担任Penwest临床开发和监管高级副总裁以及首席医疗官。加入Penwest之前，Sciascia从1997年到2000年在Quintiles，Inc.任职，担任制药和生物技术公司顾问。Sciascia博士还从2000年到2001年在TransKaryotic Therapies，Inc.（后来被Shire Pharmaceuticals Group plc收购）担任医疗总监。Sciascia博士在麻省理工学院（Massachusetts Institute of Technology）获得生物学学士学位，在哥伦比亚大学（Columbia University）获得医学学位。他是董事会认证的神经学家，获准在马萨诸塞州行医。
Thomas Sciascia,was the Senior Vice President of Clinical Development and Regulatory and Chief Medical Officer at Penwest from 2001 to 2010. Dr. Sciascia received a B.S. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. He is a board-certified neurologist licensed to practice medicine in the Commonwealth of Massachusetts.- Thomas Sciascia是我们的联合创始人，自2011年3月我们成立以来一直担任我们的首席医疗官。此前，Sciascia从2001年到2010年担任Penwest临床开发和监管高级副总裁以及首席医疗官。加入Penwest之前，Sciascia从1997年到2000年在Quintiles，Inc.任职，担任制药和生物技术公司顾问。Sciascia博士还从2000年到2001年在TransKaryotic Therapies，Inc.（后来被Shire Pharmaceuticals Group plc收购）担任医疗总监。Sciascia博士在麻省理工学院（Massachusetts Institute of Technology）获得生物学学士学位，在哥伦比亚大学（Columbia University）获得医学学位。他是董事会认证的神经学家，获准在马萨诸塞州行医。
- Thomas Sciascia,was the Senior Vice President of Clinical Development and Regulatory and Chief Medical Officer at Penwest from 2001 to 2010. Dr. Sciascia received a B.S. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. He is a board-certified neurologist licensed to practice medicine in the Commonwealth of Massachusetts.
- James Cassella
James Cassella，自2020年2月起担任Trevi Therapeutics, Inc.董事会成员。Cassella博士自2015年2月起担任生物技术上市公司Concert Pharmaceuticals, Inc.的首席开发官。在加入Concert之前，Cassella博士于2012年7月至2015年1月担任制药公司Alexza Pharmaceuticals, Inc.研发执行副总裁兼首席科学官，并于2004年6月至2012年7月担任研发高级副总裁。1989年4月至2004年4月，Cassella博士担任过多个管理职位，包括在上市生物技术公司Neurogen Corporation担任临床研究和开发高级副总裁。在加入Neurogen之前，Cassella博士是Oberlin学院神经科学助理教授。Cassella博士在达特茅斯学院获得生理心理学博士学位，在耶鲁大学医学院精神病学系完成博士后研究金，并在纽黑文大学获得心理学学士学位。
James Cassella,served as Chief Development Officer of Sun Pharmaceutical Industries Inc., a publicly traded biotechnology company, from March 2023 to September 2024, and he previously served as Chief Development Officer of Concert Pharmaceuticals, Inc., a publicly traded biotechnology company, from February 2015 until it was acquired by Sun Pharmaceutical Industries Inc. in March 2023. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc., a pharmaceutical company, from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. From April 1989 to April 2004, Dr. Cassella held various management positions, including Senior Vice President of Clinical Research and Development at Neurogen Corporation, a publicly traded biotechnology company. Dr. Cassella received a Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in Psychology from the University of New Haven.- James Cassella，自2020年2月起担任Trevi Therapeutics, Inc.董事会成员。Cassella博士自2015年2月起担任生物技术上市公司Concert Pharmaceuticals, Inc.的首席开发官。在加入Concert之前，Cassella博士于2012年7月至2015年1月担任制药公司Alexza Pharmaceuticals, Inc.研发执行副总裁兼首席科学官，并于2004年6月至2012年7月担任研发高级副总裁。1989年4月至2004年4月，Cassella博士担任过多个管理职位，包括在上市生物技术公司Neurogen Corporation担任临床研究和开发高级副总裁。在加入Neurogen之前，Cassella博士是Oberlin学院神经科学助理教授。Cassella博士在达特茅斯学院获得生理心理学博士学位，在耶鲁大学医学院精神病学系完成博士后研究金，并在纽黑文大学获得心理学学士学位。
- James Cassella,served as Chief Development Officer of Sun Pharmaceutical Industries Inc., a publicly traded biotechnology company, from March 2023 to September 2024, and he previously served as Chief Development Officer of Concert Pharmaceuticals, Inc., a publicly traded biotechnology company, from February 2015 until it was acquired by Sun Pharmaceutical Industries Inc. in March 2023. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc., a pharmaceutical company, from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. From April 1989 to April 2004, Dr. Cassella held various management positions, including Senior Vice President of Clinical Research and Development at Neurogen Corporation, a publicly traded biotechnology company. Dr. Cassella received a Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in Psychology from the University of New Haven.
- Farrell Simon
Farrell Simon，自2023年2月起担任Trevi Therapeutics, Inc.首席商务官。在此之前，他于2022年2月至2023年2月担任Trevi Therapeutics, Inc.高级副总裁、商业和战略主管，于2020年9月至2022年2月担任副总裁、美国市场营销主管。此前，Simon博士在2018年1月至2020年9月期间担任辉瑞生物制药集团总裁的高级董事、参谋长以及生物制药执行领导团队成员。在加入辉瑞之前，Simon博士在宝洁获得了一般管理、市场营销和医疗事务方面的经验。西蒙博士是西蒙癌症基金会的创始人和首席执行官，并且是大纽黑文商会的董事会成员。此前，他曾在佛罗里达大学商学院和药学院的顾问委员会任职。西蒙博士同时拥有佛罗里达大学的工商管理硕士和药学博士学位。
Farrell Simon,from February 2022 until February 2023 and Vice President, Head of US Marketing, from September 2020 until February 2022. Previously, Dr. Simon was the Senior Director, Chief of Staff to the Biopharma Group President at Pfizer Inc. and a member of the biopharmaceutical executive leadership team from January 2018 to September 2020. Prior to joining Pfizer, Dr. Simon gained general management, marketing, and medical affairs experience at Procter & Gamble. Dr. Simon is the founder and Chief Executive Officer of The Simon Cancer Foundation and is on the board of directors for the Greater New Haven Chamber of Commerce. He previously held positions on the advisory boards for the business school and the College of Pharmacy at the University of Florida. Dr. Simon holds both an M.B.A. and a Pharm.D. from the University of Florida.- Farrell Simon，自2023年2月起担任Trevi Therapeutics, Inc.首席商务官。在此之前，他于2022年2月至2023年2月担任Trevi Therapeutics, Inc.高级副总裁、商业和战略主管，于2020年9月至2022年2月担任副总裁、美国市场营销主管。此前，Simon博士在2018年1月至2020年9月期间担任辉瑞生物制药集团总裁的高级董事、参谋长以及生物制药执行领导团队成员。在加入辉瑞之前，Simon博士在宝洁获得了一般管理、市场营销和医疗事务方面的经验。西蒙博士是西蒙癌症基金会的创始人和首席执行官，并且是大纽黑文商会的董事会成员。此前，他曾在佛罗里达大学商学院和药学院的顾问委员会任职。西蒙博士同时拥有佛罗里达大学的工商管理硕士和药学博士学位。
- Farrell Simon,from February 2022 until February 2023 and Vice President, Head of US Marketing, from September 2020 until February 2022. Previously, Dr. Simon was the Senior Director, Chief of Staff to the Biopharma Group President at Pfizer Inc. and a member of the biopharmaceutical executive leadership team from January 2018 to September 2020. Prior to joining Pfizer, Dr. Simon gained general management, marketing, and medical affairs experience at Procter & Gamble. Dr. Simon is the founder and Chief Executive Officer of The Simon Cancer Foundation and is on the board of directors for the Greater New Haven Chamber of Commerce. He previously held positions on the advisory boards for the business school and the College of Pharmacy at the University of Florida. Dr. Simon holds both an M.B.A. and a Pharm.D. from the University of Florida.